Antiviral Nucleoside Analogs as Potential Chemotherapy for Trichomonas vaginalis Infections
Poster Number
3
Format
Poster Presentation
Faculty Mentor Name
Lisa Wrischnik
Additional Faculty Mentor Name
Kirkwood Land
Additional Faculty Mentor Name
Stanislaw F. Wnuk (Florida lntemational Univ.)
Abstract/Artist Statement
Trichomonas vagina/is is an anaerobic parasitic protozoan. Trichomonas is a sexually transmitted disease which is found mostly in females. It has the highest rate of infection of humans in industrialized countries. An estimated that 180 million infections are acquired annually worldwide. The estimates for North America alone are between 5 and 8 million new infections each year, with an estimated rate of asymptomatic cases as high as 50%. Symptoms ofT. vaginalis include: early delivery. low birth weight, and increased chance of getting HlV infection, AIDS, and cervical cancer. The only FDA-approved drug for this disease is metronidazole (Flagyl®). The rise in clinical drug resistance cases has spurred recent interest in the identification of alternative chemotherapies. To support such an effort, we screened a small compound library of six nucleoside analogs that have been previously characterized to have antiviral properties. Of the six compounds, two have potent inhibitory activity against Trichomonas vagina/is. We are currently determining mean inhibitory concentrations as well as determining structure activity relationships among the compounds.
Location
Wendell Phillips Center, 1st floor hallways
Start Date
3-5-2008 1:00 PM
End Date
3-5-2008 3:00 PM
Antiviral Nucleoside Analogs as Potential Chemotherapy for Trichomonas vaginalis Infections
Wendell Phillips Center, 1st floor hallways
Trichomonas vagina/is is an anaerobic parasitic protozoan. Trichomonas is a sexually transmitted disease which is found mostly in females. It has the highest rate of infection of humans in industrialized countries. An estimated that 180 million infections are acquired annually worldwide. The estimates for North America alone are between 5 and 8 million new infections each year, with an estimated rate of asymptomatic cases as high as 50%. Symptoms ofT. vaginalis include: early delivery. low birth weight, and increased chance of getting HlV infection, AIDS, and cervical cancer. The only FDA-approved drug for this disease is metronidazole (Flagyl®). The rise in clinical drug resistance cases has spurred recent interest in the identification of alternative chemotherapies. To support such an effort, we screened a small compound library of six nucleoside analogs that have been previously characterized to have antiviral properties. Of the six compounds, two have potent inhibitory activity against Trichomonas vagina/is. We are currently determining mean inhibitory concentrations as well as determining structure activity relationships among the compounds.